Source: MANUFACTURING CHEMIST

Exelan Pharmaceuticals: Cipla to acquire two US generics companies for $550m

Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
$1.2M
Est. Employees
10
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more